Skip to main content
. 2023 Feb 23;9:e2200331. doi: 10.1200/GO.22.00331

FIG 5.

FIG 5

Anti–SARS-CoV-2 IgG seroconversion rates after COVID-19 vaccination (ChAdOx1 and CoronaVac vaccine). In the ChAdOx1 vaccination group (left), the anti–SARS-CoV-2 IgG seroconversion rate in the non-CMT group was significantly higher than that in the CMT group at weeks 8 and 12 (P = .002 and P = .019), whereas the seroconversion rate at week 16 showed no difference. There were 88.6% (95% CI, 73.3 to 96.8) in the CMT group and 97.9% (95% CI, 88.7 to 99.9) in the non-CMT group, P = .436. In the CoronaVac vaccination group (right), the anti–SARS-CoV-2 IgG seroconversion rate in the non-CMT group was significantly higher than that in the CMT group (94.9% [95% CI, 82.7 to 99.4] and 70.7% [95% CI, 54.5 to 83.9], respectively; P = .007). The grey bars indicate 95% CIs. CMT, chemotherapy; IgG, immunoglobulin G; non-CMT, nonchemotherapy.